Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label Superiority Trial Comparing Emtricitabine to Abacavir Within a Triple Drug Combination in Antiretroviral-Drug Naive HIV-1 Infected Patients

NCT00002362 is registered in ClinicalTrials.gov with Triangle Pharmaceuticals as lead sponsor.

NCT NCT00002362
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00002362 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label Superiority Trial Comparing Emtricitabine to Abacavir Within a Triple Drug Combination in Antiretroviral-Drug Naive HIV-1 Infected Patients
Lead sponsor
Triangle Pharmaceuticals
Phase
Phase 3
Overall status
Suspended
Start date
August 31, 1999
Completion date
Not reported
Enrollment
Not reported
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections